The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic

Current Medical Research and Opinion

Volumn 32, Issue 4, 2016, Pages 779-785

  Al Khalili, Faris ^a,b   Lindström, Catrine ^a   Benson, Lina ^c  

^a Stockholm Heart Center   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Apixaban; atrial fibrillation; dabigatran; persistence; rivaroxaban; safety

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; VITAMIN K GROUP;

AGED; ANTICOAGULANT THERAPY; ARTHRALGIA; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIAC PATIENT; COHORT ANALYSIS; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHAGIA; DYSPNEA; EDEMA; EPISTAXIS; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART PALPITATION; HEMATURIA; HUMAN; HYPERTRANSAMINASEMIA; HYPOTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYALGIA; PATIENT SAFETY; PRURITUS; RETROSPECTIVE STUDY; TINNITUS; TRANSIENT ISCHEMIC ATTACK; BLEEDING; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; CHEMISTRY; COMPLICATION; KAPLAN MEIER METHOD; MIDDLE AGED; STROKE; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; DABIGATRAN; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT SAFETY; PYRAZOLES; PYRIDONES; RETROSPECTIVE STUDIES; RIVAROXABAN; STROKE; TREATMENT OUTCOME; VITAMIN K;

EID: 84958050246     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2016.1142432     Document Type: Conference Paper

References (18)

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361: 1139-51
2. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92
3. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
4. Beyer-Westendorf J, Ebertz F, Forster K, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2015;113:1247-57
5. Beyer-Westendorf J, Forster K, Ebertz F, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace 2015;17:530-8
6. Camm AJ, Amarenco P, Haas S, et al. XANTUS: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2015 Sep 1; pii: ehv466. [Epub ahead of print]
7. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131:157-64
8. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4
9. Lane DA, Lip GY. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation 2012;126:860-5
10. Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;34:2094-106
11. Lee SI, Sayers M, Lip GY, Lane DA. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic. Int J Clin Pract 2015;69:1341-8
12. Beyer-Westendorf J, Forster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014;124:955-62
13. Larsen TB, Rasmussen LH, Skjoth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in 'real-world' patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol 2013;61:2264-73
14. Hernandez I, Baik SH, Pinera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2015;175:18-24
15. Tamayo S, Frank Peacock W, Patel M, et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: A pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol 2015;38:63-8
16. Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014;129:961-70
17. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387-94
18. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;33:2821-30